Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

@article{Mercado2020SingleShotAV,
  title={Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques},
  author={Noe B. Mercado and Roland C. Zahn and Frank Wegmann and Carolin Loos and Abishek Chandrashekar and Jingyou Yu and Jinyan Liu and Lauren Peter and Katherine McMahan and Lisa H. Tostanoski and Xuan He and David R. Martinez and Lucy Rutten and Rinke Bos and Daniëlle van Manen and Jort Vellinga and Jerome Custers and Johannes P. M. Langedijk and Ted H. J. Kwaks and Mark J.G. Bakkers and David Zuijdgeest and Sietske Rosendahl Huber and Caroline Atyeo and Stephanie Fischinger and John S. Burke and Jared Feldman and Blake Marie Hauser and Timothy M. Caradonna and Esther A. Bondzie and Gabriel Dagotto and Makda S. Gebre and Emily Hoffman and Catherine Jacob-Dolan and Marinela Kirilova and Zhenfeng Li and Zijin Lin and Shant H. Mahrokhian and Lori F. Maxfield and Felix Nampanya and Ramya Nityanandam and Joseph P. Nkolola and Shivani Patel and John D. Ventura and Kaylee Verrington and Huahua Wan and Laurent Pessaint and Alex Van Ry and Kelvin Blade and Amanda Strasbaugh and Mehtap Cabus and Renita Brown and Anthony Cook and Serge Zouantchangadou and Elyse Teow and Hanne Andersen and Mark G. Lewis and Yongfei Cai and Bing Chen and Aaron G. Schmidt and R. Keith Reeves and Ralph S. Baric and Douglas A. Lauffenburger and Galit Alter and Paul Stoffels and Mathai Mammen and Jan van Hoof and Hanneke Schuitemaker and Dan H. Barouch},
  journal={Nature},
  year={2020},
  volume={586},
  pages={583 - 588}
}
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1–8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. 52 rhesus macaques… 

Figures from this paper

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques
TLDR
These data demonstrate that a single immunization with a relatively low dose of Ad26.COV2.S effectively protected against SARS-CoV-2 challenge in rhesus macaques, and show that a higher vaccine dose may be required for protection in the upper respiratory tract compared with the lower respiratory tract.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
TLDR
The immunogenicity and protective efficacy of this single intranasal dose vaccine confers protection against SARS-CoV-2 in non-human primates is shown, and it is a promising candidate for limiting Sars-Cov-2 infection and transmission in humans.
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
TLDR
In mice, intranasal immunization with ChAd-SARS-CoV-2-S provides durable protection against historical and emerging SARS- CoV- 2 strains, and its durability, dose-response, and cross-protective activity is assessed.
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques
TLDR
Remarkably, neutralizing antibody titers against an original SARS-CoV-2 isolate and against variants of concern were comparable, indicating a potential for broad protection afforded by ABNCoV2, which is currently in clinical testing.
Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing
TLDR
Pre-clinical data confirm efficacy of a 1-dose vaccine regimen with Ad26.COV2.S in this G614 spike SARS-CoV-2 virus variant Syrian hamster model, show the added benefit of a second vaccine dose, and demonstrate that there are no signs of VAERD under conditions of suboptimal immunity.
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
TLDR
The quality of immune responses triggered and the rapid kinetics by which protective immunity can be mounted already after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
TLDR
It is demonstrated that the mucosal vaccine was safe after multiple doses and cleared the input virus more efficiently in the nasal cavity and thus may act as a potent complementary reinforcing boost for conventional systemic vaccines to provide overall better protection.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
TLDR
Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
TLDR
Gene-based vaccination for the SARS-CoV elicits effective immune responses that generate protective immunity in an animal model, and induces T cell and neutralizing antibody responses, as well as protective immunity, in a mouse model.
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
TLDR
Data show that SARS-CoV-2 infection induced protective immunity against reexposure in nonhuman primates, and these findings have key implications for public health and economic initiatives if validated in human studies.
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
TLDR
Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 Env, Gag, and Pol and boosted with AS01B-adjuvanted Sivmac32H Env gp140 demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIVmac251 challenges that infected all controls.
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).
TLDR
This Ad26 vectored vaccine was generally safe and immunogenic at all doses tested and is a promising new vaccine vector for HIV-1.
Durability and correlates of vaccine protection against Zika virus in rhesus monkeys
TLDR
It is demonstrated that protection against ZIKV challenge in rhesus monkeys is possible for at least 1 year with a single-shot vaccine, and an effective Zika virus (ZIKV) vaccine will require long-term durable protection.
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys
TLDR
It is demonstrated that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys, and these data support the rapid clinical development of ZikV vaccines for humans.
Rapid COVID-19 vaccine development
TLDR
The benefit of developing an effective vaccine is very high, and even greater if it can be deployed in time to prevent repeated or continuous epidemics.
...
1
2
3
4
...